Quick Takeaways
- Commodore Capital LP filed SCHEDULE 13G for RELMADA THERAPEUTICS, INC. Common stock, $0.001 par value per share (RLMD).
- Disclosed ownership: 5.1%.
- Date of event: 27 Apr 2026.
Commodore Capital LP - 27 Apr 2026 SCHEDULE 13G Report for RELMADA THERAPEUTICS, INC. Common stock, $0.001 par value per share (RLMD)
- Filing Manager
- Commodore Capital LP
- Reporting Manager
- Commodore Capital LP
- Symbol
- RLMD
- Shares outstanding
- 107,951,510 shares
- Disclosed Ownership
- 5,505,527 shares
- Ownership
- 5.1%
- Form type
- SCHEDULE 13G
- Filing time
- 04 May 2026, 16:25:12 UTC
- Date of event
- 27 Apr 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Commodore Capital LP disclosed 5.1% ownership in RELMADA THERAPEUTICS, INC. Common stock, $0.001 par value per share (RLMD) on 27 Apr 2026."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 04 May 2026, 16:25.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Commodore Capital LP | 5.1% | 5,505,527 | 0 | 5,505,527 | Michael Kramarz | Managing Partner | |
| Commodore Capital Master LP | 5.1% | 5,505,527 | 0 | 5,505,527 | Michael Kramarz | Authorized Signatory | |
| Robert Egen Atkinson | 5.1% | 5,505,527 | 0 | 5,505,527 | Robert Egen Atkinson | Authorized Signatory | |
| Michael Kramarz | 5.1% | 5,505,527 | 0 | 5,505,527 | Michael Kramarz | Authorized Signatory |